Blood pressure (BP) is the major determinant of cerebral perfusion yet blood pressure management in acute stroke is complex and controversial. Optimized blood pressure management may improve outcomes in patients with ischemic and hemorrhagic stroke although the available data are conflicting and target BP goals are not well defined. We review the current literature, published guidelines, and emerging research on this important topic. Additionally, the treatment algorithm which we employ is discussed.
Introduction
Blood pressure (BP) is the major determinant of cerebral perfusion, yet BP management in acute stroke is complex and controversial. Stroke is the third leading cause of death and a leading cause of disability in the United States, with an annual incidence of 700-800 000 cases per year. [1] [2] [3] Stroke is extremely expensive and is estimated to cost the United States 65.5 billion dollars in 2008. 2 The global burden of stroke is even more staggering, with an estimated incidence of 15 million cases per year. 4 Five million of these patients die and another five million are left permanently disabled. 4 Optimized BP management may improve outcomes in these patients. Unfortunately, the data are conflicting and target BP goals are not well defined.
Elevated BP is incredibly common during an acute stroke, with 60-80% of patients having a systolic blood pressure (SBP) 4140 mm Hg. [5] [6] [7] [8] In 20% of these patients this represents the first diagnosis of hypertension. 9 The acute hypertensive response is partially due to changes in cerebral perfusion, and may serve to increase blood flow to ischaemic portions of the brain. There are many other contributing factors, including undiagnosed hypertension, inadequately treated hypertension, damage to autonomic centres in the brain, stress response and elevated intracranial pressure (ICP). 10 This early elevation in BP spontaneously decreases over days, with an average decline of 20/10 mm Hg by day 10. 7, 11 This spontaneous resolution appears to be facilitated by arterial recanalization. 12 Unfortunately, increased cerebral perfusion comes at a cost. Increased blood flow through infarcted tissue may worsen cerebral oedema and increase the risk of haemorrhagic transformation. A meta-analysis incorporating over 10 000 ischaemic and haemorrhagic stroke patients showed that elevated SBP, diastolic blood pressure (DBP) and mean arterial pressure (MAP) were all associated with worse outcome. 8 Clearly, there is a fine balance between optimal perfusion and adverse events. We will review the pathophysiology of cerebral perfusion, the management of BP after acute stroke, published treatment guidelines and emerging clinical data.
Pathophysiology
Cerebral perfusion pressure (CPP) is equal to MAP minus ICP. Under normal circumstances, ICP is negligible and therefore CPP is determined almost entirely by MAP. Cerebral blood flow (CBF) is a function of CPP and cerebrovascular resistance (CVR), where CBF ¼ CPP/CVR. Although MAP may fluctuate dramatically over time, CBF is normally held constant at 50 ml/100 g brain tissue per minute. 13 CBF is maintained by adjusting CVR. This is cerebral autoregulation; it is depicted graphically in Figure 1a .
Autoregulation is the incompletely understood ability of the brain's resistance vessels to dilate or constrict in response to changes in MAP. This vasomotor response occurs primarily at the level of the arteriole. Autoregulation maintains a constant CBF between an MAP of 60-150 mm Hg. [14] [15] [16] As MAP falls, arteriolar dilation occurs to decrease CVR and maintain CBF. When these vessels become maximally dilated, oxygen extraction fraction (OEF) may increase to satisfy high cerebral metabolic demands. If MAP continues to fall after vessel dilation and OEF have been maximized, metabolic needs are not met and brain tissue becomes ischaemic.
When MAP is increased, arterioles constrict to raise CVR and maintain a constant CBF. However, as MAP surpasses the upper threshold of autoregulation, arterioles are forced open by high intra-luminal pressures. Forced dilation causes disruption of the blood-brain barrier, vasogenic oedema, increased ICP and haemorrhage. In patients with chronic hypertension, the entire autoregulatory curve is shifted to the right (Figure 1b) . 15 Constantly increased CVR leads to hypertrophy and stiffening of vessel walls. This makes the brain intolerant of relative hypotension and causes decreased CBF at MAPs that would otherwise be well tolerated.
In the setting of an acute stroke, the ability to adjust CVR is decreased and autoregulation is impaired. This impairment is most prominent within and around the stroke, but may be present globally. 17, 18 As a result, the relationship between CBF and CPP becomes more linear (Figure 1c ). Changes in MAP may cause dramatic changes in CBF. This puts the brain at risk for further infarction when MAP falls and cerebral oedema, elevated ICP and haemorrhage when MAP rises.
Ischaemic stroke
Ischaemic stroke is due to the abrupt loss of CBF to a portion of the brain. At presentation, clinic deficits in acute ischaemic stroke represent both an infracted core, which has already died, and a surrounding area that is not yet irreversibly damaged, the ischaemic penumbra ( Figure 2 ). If normal CBF is restored to the penumbra before the tissue dies, it may regain function. The time window for saving this tissue at risk depends on how severely CBF is impaired (Figure 3 ). The primary goal of stroke care is to preserve as much of the penumbra as possible, which means optimizing BP and CBF.
The relationship between BP and outcome after ischaemic stroke is complicated. Elevated BP may be a marker for stroke severity. 19 It can also serve as a prognostic factor. Studies have shown an association between low BP and poor outcome, as well as an association between elevated BP and poor outcome. 8, [20] [21] [22] BP variability is another important consideration that may impact outcome. 11, 23, 24 These seemingly contradictory findings can be explained by a U-shaped relationship between BP and outcome after ischaemic stroke. 5, 25 This relationship is expected given the physiology of CBF and the loss of autoregulation that accompanies acute stroke.
There is a small range of BP that is optimal for the penumbra; above and below this range further damage ensues. The International Stroke Trial (IST) demonstrated this in over 17 000 patients. There was a 17.9% increase in early death for every 10 mm Hg rise in SBP above 150 mm Hg and a 3.8% increase for every 10 mm Hg drop in SBP below 150 mm Hg. 5 A smaller study found a similar U-shaped relationship between BP and outcome. 25 However, in this study the inflection point was higher, and SBP above and below 180 mm Hg were associated with neurologic deterioration and worse outcome. The optimal BP is not known, and may differ among individuals and across stroke subtypes. 26 Evidence against treating hypertension in acute ischaemic stroke Low BP decreases cerebral perfusion and may potentiate infarction in the ischaemic penumbra. SBP may drop by as much as 28% in the first 24 h after acute stroke, independent of treatment, and this decline is associated with poor outcome. 27 There are a multitude of case reports with patients experiencing neurologic deterioration after moderate BP reduction. 28 Several clinical trials have found an association between antihypertensive therapy in acute stroke and worse outcome. The Beta-Blocker Stroke Trial looked at low dose b-blockade in acute stroke. Patients presenting within 48 h were randomized to placebo, atenolol 50 mg daily or slow release propranolol 80 mg daily. 29 The trial was stopped early because of an increased risk of death in the treatment groups. The Intravenous Nimodipine West European Stroke Trial (INWEST) showed that treatment with nimodipine was associated with decreased BP and increased chance of death or dependency. 30 This study had a very high rate of hypotension, with 60% of patients having one or more drop in DBP o60 mm Hg. This undoubtedly contributed to the effect on outcome. A metaanalysis of calcium channel blockers in acute stroke evaluating 29 trials and 7665 patients found that among published trials there was no effect of treatment. 31 Subgroup analysis of methodologically sound and unpublished trials (identified by contacts with investigators and pharmaceutical companies) found a negative effect, with worse outcomes in the treatment group. 31 A 2000 Cochrane Review using data from 32 trials encompassing 5368 patients found that b-blockers and calcium channel blockers appeared to increase disability and case fatality. However, they noted significant variability in baseline BP between studies and concluded that there was insufficient evidence to reliably evaluate the effect of vasoactive drugs. 32 Evidence in favour of treating hypertension in acute ischaemic stroke Elevated BP may increase cerebral oedema after an acute infarction and raise the risk of haemorrhagic conversion. [33] [34] [35] Antihypertensive medications may limit this process. Animal data suggest that BP reduction may reduce infarct size. 36 In addition to their haemodynamic effects, antihypertensive medications may have class-specific effects that further benefit stroke patients. It has been postulated that angiotensin receptor antagonism may increase CBF and vasomotor reactivity. [36] [37] [38] Antihypertensive therapies have been used in acute cardiac and renal disease for tissue protection, and these agents may have neuroprotective properties as well.
The Acute Candesartan Cilexetil Evaluation in Stroke Survivors (ACCESS) study was a doubleblinded, placebo-controlled evaluation of candesartan in acute stroke. 39 Enrolled patients had to have two BP readings with a mean SBP X200 mm Hg and/or a DBP X110 mm Hg 6-24 h after admission or SBP X180 mm Hg and/or DBP X105 mm Hg 24-36 h after admission. Patients with internal carotid artery stenosis 470% were excluded. There was no difference in the primary end point of disability at 90 days, but 12 month mortality and the incidence of vascular events were significantly lower in the treatment group, with an odds ratio of 0.475 (95% CI 0.252-0.895). 39 The authors proposed that candesartan facilitated vascular growth and remodelling, thus counterbalancing the haemodynamic effects of lower BP. These results must be interpreted cautiously. The mean BP in ACCESS was significantly higher than in INWEST (SBP 196 versus 162 mm Hg). 30, 39 This difference may account for the difference in outcome. Also, a large portion of the benefit in ACCESS was due to lower rates of cardiovascular events in the treatment group rather than neurologic recovery.
A smaller study of lisinopril, given within 24 h of acute ischaemic stroke, showed a significant reduction in BP at 4 h, but no difference in functional outcome at 90 days. 40 A meta-analysis of two studies evaluating transdermal nitroglycerin in a total of 127 patients also showed a statistically significant reduction in BP with no difference in outcome. 41 Post hoc analysis of the National Institute of Neurological Disorders and Stroke (NINDS) recombinant tissue plasminogen activator (rt-PA) treatment trial showed no significant difference between placebo-treated patients who received antihypertensives and those who did not. 42 These trials together imply that antihypertensive therapy may be safe in the setting of acute stroke, but do not show a benefit to the patient. Timing is another critical consideration that has not been addressed in these, or any other, trials. There may be a window of time acutely when BP reduction exacerbates cell death in the penumbra. There may also be intervals when drugspecific neuroprotective and/or vascular growth promoting properties can be exploited. There are unfortunately no good clinical data to guide timing of early antihypertensive medication administration after acute stroke.
Blood pressure and thrombolysis
Patients who receive intravenous or intra-arterial thrombolysis are at increased risk for haemorrhagic conversion. Tight BP control is very important in these patients. In the Australian streptokinase study, SBP 4165 mm Hg was associated with a 25% increased risk of major intracranial haemorrhage. 43 In the second European Cooperative Acute Stroke Study, SBP and systolic variability were associated with an increased risk of petechial haemorrhage after thrombolysis. 24 The NINDS rt-PA stroke treatment trial recommended a BP of p185/110 mm Hg before treatment and p180/105 mm Hg after treatment. 44 In the trial, elevated BP was associated with an increased risk of symptomatic haemorrhage. 45 Failure to adhere to these guidelines in routine clinical practice has also been shown to increase the rate of symptomatic haemorrhage. [46] [47] [48] It has been suggested that patients who require aggressive measures to maintain a BP lower than 185/ 110 mm Hg should not receive thrombolysis. However, there is growing evidence to support the use of thrombolytics in these patients. Martin-Shild et al. 49 conducted a retrospective cohort study of 178 patients with acute ischaemic stroke who were treated with rt-PA. Fifty of these patients required BP lowering, 24 of whom received intravenous nicardipine. There was no difference in outcome in those who required treatment compared to those who did not. When comparing those treated with intravenous nicardipine to those treated with labetalol alone, there was no significant difference between groups. Because recanalization by rt-PA may cause a spontaneous decline in BP, patients require close monitoring and medication titration to ensure their BP does not fall to an unacceptable level. 12 
Induced hypertension
In acute ischaemic stroke, low BP is associated with worse outcomes. 5, 25 Severe hypotension is rare after stroke. In the IST, only 5% of the 17 398 patients had an SBP o120 mm Hg. 5, 25 If an acute stroke patient is hypotensive, clinicians should search for an underlying aetiology, including volume depletion, myocardial infarction, cardiac arrhythmia, blood loss and aortic dissection. If any of these entities are found, they must be treated rapidly. If there is no correctable cause for hypotension, the patient fails to respond to volume resuscitation, and/or there is fluctuation in neurologic symptoms, induced hypertension may be considered.
Pharmacologically induced hypertension for acute ischaemic stroke has been used since 1950s. 50 More recently, studies have shown that induced hypertension may increase CBF and restore perfusion to the penumbra. 18, 51 Small studies have demonstrated clinical improvement with induced hypertension as late as 9 days after stroke onset. 52 Koenig et al. 53 conducted a clinical trial of induced hypertension in 100 patients with acute ischaemic stroke and diffusion-perfusion mismatch on magnetic resonance imaging (MRI), which is believed to represent viable penumbral tissue. Forty-six patients were treated with induced hypertension and 54 received standard therapy. The stated goal was to raise BP by 10-20%. There was a trend towards higher MAP in the induced hypertension group with a statistically significant difference at day 3 (103±14 versus 96±13 mm Hg). The induced hypertension group had an increased frequency of carotid stenosis and a larger volume of restricted perfusion on baseline MRI. There was a nonsignificant reduction in stroke severity (three point median decrease on the National Institutes of Health Stroke Scale) in the induced hypertension group. Adverse events were similar between groups. Patients treated with induced hypertension were more likely to be admitted to the neurologic intensive care unit and had a longer length of stay by an average of 4 days. Mistri and colleagues performed a systemic review of induced hypertension, including 12 studies and 319 patients. Included studies varied considerably with respect to inclusion/exclusion criteria, duration/method of induced hypertension and outcome measures. As a result, formal metaanalysis was not possible. The authors concluded that although induced hypertension appears safe, larger scale clinical trials are needed to address this issue. 54 
Current guidelines
Current treatment guidelines, published by the European Stroke Organization (ESO) and American Heart Association (AHA), generally do not recommend antihypertensive therapy in acute stroke. These recommendations acknowledge the conflicting and incomplete nature of the evidence. Both the ESO and the AHA recommend BP lowering to below 185/110 mm Hg in patients eligible for thrombolysis (Evidence Class I Level B). 55, 56 After rt-PA, BP should be maintained below 180/105 mm Hg. 55, 56 Labetalol, nitropaste and nicardipine are all firstline options in these patients, and the use of intravenous nicardipine is not a contraindication to rt-PA. 56 For patients not undergoing thrombolysis, cautious BP lowering is recommended when SBP 4220 mm Hg and/or DBP 4120 mm Hg (Evidence Class I Level C). 55 , 56 The AHA guidelines conclude that there is no sufficient evidence to recommend a specific agent, but the goal should be to reduce BP by no more than 15% during the first 24 h. Hypotension after acute stroke should prompt the clinician to search for and treat the underlying aetiology, as noted above. Initial treatment should be with volume expansion as dehydration is common in acute ischaemic stroke. 55 , 56 The AHA guidelines specifically address induced hypertension and conclude that it should be reserved for 'exceptional cases'; it is not recommended outside of clinical trials (Evidence Class III Level B).
For patients with a history of hypertension, there are almost no data on management of their preexisting antihypertensive medications. European guidelines do not address this issue at all. The AHA guidelines recommend restarting home medications at 24 h if the patient is stable. The seventh report of the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure recommends that BP be maintained at approximately 160/100 mm Hg until the patient is neurologically stable. 57 Emerging clinical data Both the ESO and AHA guidelines comment on the need for large, well-designed trials to guide BP management in acute ischaemic stroke. The Controlling Hypertension and Hypotension Immediately Post-Stroke study is a multi-centre, placebo-controlled, double-blinded study enrolling patients with acute ischaemic strokes. Hypertensive patients, defined by an SBP 4160 mm Hg, enrolled within 36 h are randomized to treatment with lisinopril, labetalol or placebo. 58 Hypotensive patients, defined by an SBP o140 mm Hg, enrolled within 12 h are randomized to treatment with phenylephrine or placebo to a target SBP of 150 mm Hg. The primary outcome measure is death and dependency at day 14. Pilot data from the hypertension arm of the study, with 179 patients, was presented at the 2008 International Stroke Conference. Patients in the placebo arm were 2.2 times more likely to be dead at 90 days. 59 A larger, phase III trial is required to confirm these interesting early results and will hopefully help to define the optimal BP for patients with acute ischaemic stroke.
Another important ongoing study is the Continue Or Stop Post-Stroke Antihypertensives Collaborative Study. 60 This study is designed to evaluate the optimal management of pre-existing antihypertensives. In the study patients will be randomized to either continue or discontinue pre-existing antihypertensives. The primary outcome will be death and disability at 2 weeks and 6 months. The Scandinavian Candesartan Acute Stroke Trial is a larger trial of candesartan in acute stroke, with a goal of 2500 patients, and it may confirm the findings of ACCESS. 61 Finally, the Efficacy of Nitric Oxide in Stroke trial is looking at the effects of transdermal nitroglycerin as well as discontinuing pre-existing antihypertensives on outcome. 61 These studies will hopefully add greatly to our ability to manage BP in acute ischaemic stroke, answering important questions about whether hypertension should be treated, what agents to use, when to start them and what to do with pre-existing antihypertensive drugs.
Intracerebral haemorrhage
Spontaneous intracerebral haemorrhage (ICH) accounts for 10-15% of all strokes with an estimated worldwide incidence of 10-20 cases per 100 000 population. 62, 63 This is a highly morbid disease with an estimated 1-year mortality of 38%. 62 The aetiology of spontaneous ICH is divided into primary and secondary causes. Primary ICH is most often the sequela of chronic hypertension or cerebral amyloid angiopathy, which together account for 78-88% of cases. 64 Secondary ICH may result from disorders of coagulation, vascular malformations or neoplasms. Elevations in SBP greater than 140 mm Hg are reported in the majority (75%) of patients with acute spontaneous ICH. 6 Elevations in BP in acute ICH have been correlated with poor outcomes in some, but not all studies. 8, [65] [66] [67] Treatment of elevated BP in the setting of spontaneous primary ICH remains controversial because there are unclear data to guide therapeutic decision-making.
Evidence against treating hypertension in acute ICH
Arguments against lowering elevated BP in acute ICH are based on the theoretical risk that lowering BP will lower CPP and induce ischaemia in a zone of hypoperfused tissue surrounding the haematoma. 68 The CBF in normotensive and chronically hypertensive people is the same. However, chronic hypertensive changes in the vessel wall limit its ability to vasodilate in response to hypotension so that CBF falls and tissue becomes ischaemic. A few animal studies have demonstrated a global decrease in CBF after ICH, with the lowest flow reported in the area adjacent to the haematoma. 69, 70 Kidwell et al. 71 reported MRI apparent diffusion coefficient data that indicated there may be a perihaematomal area of ischaemia, similar to the penumbra of ischaemic stroke. A retrospective study showed an increase in mortality in ICH patients that had a rapid decline in BP in the first 24 h. 72 These studies suggest that aggressive BP lowering could pose a risk of perihaematomal infarction or other major adverse events and should be avoided.
Evidence for aggressive BP management in acute spontaneous ICH The primary reason for early and aggressive BP control in patients with acute ICH is to reduce the risk of haemorrhagic expansion. Approximately 38% of patients with acute ICH have haemorrhagic expansion within the first 24 h, 20-25% within the first hour of presentation. 73, 74 Studies have shown a relationship between BP at presentation and haemorrhagic expansion. 75, 76 Whether hypertension is the cause of haematoma growth or the effect of elevated ICP remains unclear. Although intuitively beneficial, reducing or preventing haemorrhagic expansion has not been clearly associated with acute hypertension or shown to affect clinical outcomes that may be affected by a myriad of potential confounders including cerebral oedema, elevated ICP or systemic medical complications.
Despite early evidence to the contrary, multiple neuroimaging studies have not demonstrated an area of ischaemia surrounding the haematoma. Using positron emission tomography (PET), investigators have shown no change in CBF, cerebral metabolic rate for oxygen or OEF both in dogs and in humans with ICH. [77] [78] [79] This correlates with MRI studies that have shown no perihaematomal ischaemia. [80] [81] [82] One small prospective study of 14 ICH patients showed that a 15% pharmacologic reduction in MAP (mean 142 ± 10 to 119 ± 11 mm Hg) using nicardipine or labetalol did not reduce global or regional perihaematomal CBF measured with PET and 15 O-water. 83 In an observational cohort of 98 patients with ICH, there was no relationship between BP or heart rate parameters, individually or in combination, with haematoma growth. 84 In a trial of recombinant factor VIIa for ICH involving 382 patients with CT scans within 3 h and at 24 h after symptom onset, there was also no relationship between baseline BP and haemorrhagic expansion. 85 The INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage) trial randomized 404 patients with spontaneous ICH and hypertension (SBP ¼ 150-220 mm Hg) within 6 h of presentation to either 'guideline-based' therapy (target SBP ¼ 180 mm Hg) or 'early intensive' treatment (target SBP ¼ 140 mm Hg). 86 There was a significant reduction in haematoma growth from 36.3% in the guideline group to 13.7% in the intensive group (difference 22.6%, 95% CI 0.6-44.5%; P ¼ 0.04) at 24 h. This reduction was slightly dampened when it was corrected for initial haematoma volume; the absolute risk reduction for haematoma expansion 433% or 12.5 ml was decreased from 23% in the guideline group to 15% in the intensive treatment arm (difference 8, 95% CI 1.0-17%; P ¼ 0.05). However, intensive BP lowering did not alter the chances of having an adverse event, and there was no significant change in the secondary end points, including death or dependency.
Current guidelines
Current treatment guidelines, published by the AHA and the European Stroke Initiative (EUSI), recommend individualized treatment for acute elevations of BP in patients with ICH based on underlying factors such as chronic baseline hypertension, ICP, patient age, aetiology and timing of the haemorrhage.
87, 88 The current recommendations were based on the available incomplete and conflicting data from animal models, small uncontrolled trials and the traumatic brain injury literature.
The 2007 AHA guidelines for management of spontaneous ICH in adults suggest the following treatment goals for elevated BP (Evidence Class IIb Level C). 87 Both the AHA and EUSI guidelines for management of patients with spontaneous ICH recommend initiating antihypertensive therapy in an intensive care or dedicated stroke unit with continuous intraarterial pressure monitoring if available (Evidence Class I Level B). There are several intravenous drugs in either bolus or continuous infusion preparations recommended in the AHA and EUSI guidelines for the treatment of elevated BP in ICH patients. [87] [88] [89] These medications are detailed in Table 1 .
Emerging clinical data
The available treatment guidelines are limited because they were published before the completion of two relatively large randomized trials, INTERACT (described above) and ATACH (Antihypertensive Treatment of Acute Cerebral Hemorrhage).
The ATACH pilot trial was designed to assess the tolerability of goal directed BP therapy in ICH patients presenting within 6 h of their symptoms with SBP 4200 mm Hg. 90 A total of 58 patients were enrolled in ATACH and randomized to treatment with an i.v. nicardipine infusion for 24 h targeted to one of three different predefined SBP goals (170-200, 140-170 or 110-140 mm Hg). The results of ATACH were presented at the 2008 International Stroke Conference but have only been published in abstract form. 91 There were no significant differences in safety end points or in-hospital mortality between the three treatment arms. The presenters concluded that aggressive SBP control to a goal of 110-140 mm Hg in the first 24 h following an ICH is safe, well tolerated and has a low risk of haematoma expansion, neurologic worsening or in-hospital mortality.
The current evidence is leading towards early, aggressive management of elevated BP in the setting of acute ICH. This strategy seems to prevent ICH expansion, though has not been proven to improve clinical outcomes. Though not perfect, the current guidelines provide a good starting place for developing treatment paradigms for hypertension in acute ICH. The recent data provided by the INTERACT and ATACH trials indicate that it may be safe to aggressively lower SBP below 140 mm Hg in these patients. 86 ,91 INTERACT 2 is now recruiting patients and ATACH 2 is being planned. INTERACT 2 plans to enrol 2800 patients with the primary outcome being a composite of death and dependency at 3 months. These larger phase III studies will be designed to better demonstrate whether aggressive BP control can improve clinical outcomes.
Conclusions
Decisions about the management of hypertension after stroke are limited by a lack of high-level evidence from clinical trials. In both ischaemic and haemorrhagic stroke, the optimum BP range in the first hours to days is not known. It is not clear when oral agents should be started and which agents should be first-line drugs. Whether preexisting antihypertensives should be continued is not known. Published practice guidelines and our recommendations (presented in Figure 4 ) are based at least as much on pathophysiology as on the available evidence.
In ischaemic stroke, the data consistently demonstrate that elevated BP after thrombolysis is harmful. We agree with published guidelines and recommend that BP be less than 185/110 mm Hg before thrombolysis and 180/105 mm Hg for at least the first 24 h after thrombolysis. In the absence of thrombolysis, we agree with the AHA guidelines and prefer to withhold treatment unless SBP 4220 mm Hg or DBP 4120 mm Hg. The AHA guidelines do not comment on MAP, but we recommend treatment if MAP 4140 mm Hg. We initially treat with short acting i.v. agents such as labetalol, enalaprilat or nicardipine. We transition to oral agents when the patient has been neurologically stable for 24 h. We hold all pre-existing antihypertensives acutely, except for b-blockers that we continue at 50% of the home dose to prevent rebound tachycardia. Induced hypertension is not used routinely, but may be reserved for hypotension that is refractory to aggressive fluid resuscitation and/or fluctuation in the neurologic exam that is clearly dependent on haemodynamic parameters.
For haemorrhagic stroke, we recommend an aggressive approach, based on the data from INTER-ACT and ATACH. If ICP is normal, SBP at presentation is o160/90 mm Hg, and there is no pre-existing history of hypertension, we maintain BP o140/ 80 mm Hg. If BP at presentation is 4160/90 mm Hg or there is a history of hypertension, we maintain BP o160/90 and/or MAP o110 mm Hg. If there is a clinical concern for elevated ICP, a monitor is placed Consider oral antihypertensives when neurologically stable for 24 hours.
• BP<185/110 mm Hg prior to thrombolysis.
• Post-treatment maintain BP<180/105 mm Hg.
• IV labetalol 10-20 mg or continuous infusion of nicardipine (5 mg/hr initial dose) preferred.
• If on beta blocker, reduce dose by 50%.
• Hold all other pre-existing antihypertensives.
• If SBP>220, DBP>120, or MAP>140 mm Hg lower BP by no more than 15%.
• IV labetalol 10-20 mg, IV enalaprilat 1.25-2.5 mg, or continuous infusion of nicardipine (5 mg/hr initial dose) preferred.
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